| Outcome | Total Comparisons/Studies | All Studies | Oxybutynin ER | Solifenacin | Total Studies | Oxybutynin ER | Total Studies | Fesoterodine |
|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI)(Minassian et al., 2007) | RR (95% CI)(Herschorn et al., 2011) | RR (95% CI)(Sand et al., 2004) | RR (95% CI)(DuBeau et al., 2012) | ||||
|
| ||||||||
| Versus Oxybutynin IR | Versus Tolterodine IR | Versus Tolterodine ER | ||||||
| AEs | 1 | 0.40 (0.15–1.12) | 0.40 (0.15–1.12) | 0.40 (0.15–1.12) | 1 | 1.08 (0.52–2.23) | 1 | 3.15 (1.81–5.49) |
| Constipation | 0 | -- | -- | -- | 0 | -- | 1 | 2.15 (0.39–11.67) |
| Dizziness | 0 | -- | -- | -- | 0 | -- | -- | |
| Dry Mouth | 1 | 0.1 (0.01–1.74) | -- | 0.1 (0.01–1.74) | 0 | -- | 1 | 2.79 (1.00–7.78) |
| Headache | 0 | -- | -- | -- | 0 | -- | 1 | 3.22 (0.34–30.86) |
| Lost to Follow-up | 0 | -- | -- | -- | 1 | 1.76 (0.31–10.15) | 0 | -- |
| Personal Reasons | 0 | -- | -- | -- | 1 | 3.53 (0.38–32.89) | 0 | -- |
| Protocol Violation | 0 | -- | -- | -- | 1 | 0.39 (0.02–9.39) | 0 | -- |
| Total Discontinuation | 1 | 0.73 (0.39–1.36) | 0.73 (0.39–1.36) | -- | 0 | -- | 0 | -- |
| Unsatisfactory Therapeutic Effect | 0 | -- | -- | -- | 1 | 3.53 (0.38–32.89) | 0 | -- |
| Vision Blurred | 0 | -- | -- | -- | 0 | -- | 1 (0)† | † |
| Withdrew Consent | 0 | -- | -- | -- | 1 | 5.87 (0.29–119.44) | 0 | -- |
Only reported if both studies reported outcomes
*
= I2 >25%
AEs = Adverse Events; CI = confidence intervals; ER = extended release; IR = immediate release; OR= odds ratio